Imugene Limited

Imugene Limited

Biotechnology Research

Sydney, New South Wales 7,247 followers

Bringing Effective New Treatments And Options To Patients Who Need Them

About us

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. ASX: IMU

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Sydney, New South Wales
Type
Public Company
Founded
2013
Specialties
Immuno-oncology, Cancer Vaccines, Her-2+ cancers, Mimotopes, PD-1, biotechnology, immunotherapy, biotech, immune system, cancer experts, B-cell peptide vaccines, b-cell, B-cell vaccine technology, cancer therapy, drug development, and immune checkpoint inhibitor monoclonal antibodies

Locations

  • Primary

    37 Bligh St

    Suite 1006, Level 10

    Sydney, New South Wales 2000, AU

    Get directions

Employees at Imugene Limited

Updates

Similar pages

Browse jobs

Funding

Imugene Limited 3 total rounds

Last Round

Post IPO equity

US$ 3.3M

See more info on crunchbase